Is Bio-Electric Medicine the Next Frontier of Therapy for Coronavirus Victims?

Just Published - Dr. Patrick Nemechek proposes new technology to suppress COVID-19 cytokine storm.

    OVERLAND PARK, KS, July 02, 2020 -- Nemechek Technologies, LLC announced the publication of a peer-reviewed article by Patrick Nemechek D.O. in The Journal of Integrative Clinical Medicine. Entitled, 'Transcutaneous Auricular Vagus Nerve Stimulation Holds the Potential to Suppress the COVID-19 Cytokine Storm', the article explains the science behind the inflammatory reflex and how vagus nerve stimulation may be a cost-effective and life-saving therapy.

Patients hospitalized with COVID-19 are predominantly dying of respiratory failure due to a surge of pro-inflammatory protein molecules called cytokines that regulate inflammation. In some COVID-19 patients, an excessive inflammatory reaction known as a "cytokine storm" will trigger acute respiratory distress syndrome. This severe form of lung injury is why many patients require mechanical ventilation.

Dr. Nemechek argues that a potential solution to this deadly, unregulated immune response may be a mild electrical current applied to the vagus nerve. His method, known as transcutaneous auricular vagus nerve stimulation (taVNS), delivers a barely perceptible micro-current through a specially designed clip that fits comfortably on the ear.

Stimulation of the afferent vagus nerve fibers in certain portions of the ear activates the inflammatory reflex. Much like the baroreflex that controls blood pressure, the inflammatory reflex signals the body to naturally regulate an immune response. Human studies show that VNS is effective in suppressing a range of pro-inflammatory cytokines in septic shock and improves clinical symptoms in a range of pathologies. Additionally, animal studies suggest that VNS may also be capable of mitigating abnormal clotting seen in more severe COVID-19 patients.

taVNS is largely unrecognized as a therapeutic tool to regulate the cytokine storm, and potentially coagulation abnormalities, in hospitalized patients. It is safe, non-invasive, easy to us, and does not interfere with other therapies. Importantly, a single taVNS device can be shared among many patients with minimum sterilization.

About Nemechek Technologies, LLC

Founded by Patrick Nemechek, D.O. and Jean Nemechek in 2019, Nemechek Technologies, LLC is a privately held manufacturer of bio-electronic medicine. Their first product, the Vitality Smartcable, is the first taVNS neuromodulator that runs on your smartphone. Nemechek Technologies has offered to supply Vitality Smartcable devices for investigator-initiated clinical trials of taVNS therapy for COVID-19.

With 20 years' experience as an HIV physician and researcher, Dr. Nemechek was awarded U.S. Patent No. 10,335,396 for his method of using vagus nerve stimulation to lower inflammation and reversing autonomic nervous system damage. The Nemechek Protocol®, which focuses on the reduction of chronic inflammation, includes the use of transcutaneous vagus nerve stimulation. Dr. Nemechek has treated more than 1,000 patients with vagus nerve stimulation therapy over the past ten years at his clinic near Phoenix, Ariz.

Media Contact:
Mike Nemechek
Nemechek Technologies, LLC

# # #

Contact Information
Mike Nemechek
Nemechek Technologies, LLC

Overland Park, Kansas
United States
Voice: 913-219-1239
Website: Visit Our Website

If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact Dragstrip Communications Newswire. We are unable to assist you with any information regarding this release. Dragstrip Communications Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.